Pfizer

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

24 Mar 2026

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

23 Mar 2026

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

23 Mar 2026

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pfizer common stock at a pric

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

23 Mar 2026

Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic hor

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

23 Mar 2026

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients initia

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

27 Feb 2026

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease a

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

27 Feb 2026

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancer Pivotal results from the Phase 3 portion with mFOLFOX6 of the BREAK

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

17 Feb 2026

BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E -mutant metastatic colorectal cancer Results

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

06 Feb 2026

Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMP

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

06 Feb 2026

Program offers significant savings on over 30 brands spanning women’s health, migraine, arthritis, rare disease and more Affirms Pfizer’s commitment to reduce drug costs for millions of Americans thro

View details about the software product Informachine News Trackers